GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions

Feladilimab Phase II Combination Study With Keytruda Halted

 
• By John Davis
gloomy autumn day
A Disappointing Day For GSK • Source: Shutterstock

More from Anticancer

More from Therapeutic Category